### Résumé

131I or ^{90}Y still remains ineffective for solid and radioresistant tumour treatment. Previous simulations have revealed that an increase in the number of ^{90}Y labelled to each antibody or nanoobject could be a solution to improve treatment output. It now seems important to assess the treatment output and toxicity when radionuclides such as ^{90}Y, ^{177}Lu, ^{131}I, ^{124}I, and ^{188}Re are used. Tumour control probability (TCP) and normal tissue complication probability (NTCP) curves versus the number of radionuclides per nanoobject were computed with MCNPX to evaluate treatment efficacy for solid tumours and to predict the incidence of surrounding side effects. Analyses were carried out for two solid tumour sizes of 0.5 and 1.0 cm radius and for nanoobject (i.e., a radiolabelled antibody) distributed uniformly or nonuniformly throughout a solid tumour (e.g., Non-small-cell-lung cancer (NSCLC)). ^{90}Y and ^{188}Re are the best candidates for solid tumour treatment when only one radionuclide is coupled to one carrier. Furthermore, regardless of the radionuclide properties, high values of TCP can be reached without toxicity if the number of radionuclides per nanoobject increases.]]>

langue | Anglais |
---|---|

Numéro d'article | 284360 |

journal | Computational and Mathematical Methods in Medicine |

Volume | 2015 |

Les DOIs | |

état | Publié - 2015 |

### Empreinte digitale

### Citer ceci

^{90}Y-,

^{177}Lu-,

^{131}I-,

^{124}I-, and

^{188}Re-Nanoobjects: Choice of the best radionuclide for solid tumour treatment by using TCP and NTCP concepts. DOI: 10.1155/2015/284360

}

^{90}Y-,

^{177}Lu-,

^{131}I-,

^{124}I-, and

^{188}Re-Nanoobjects: Choice of the best radionuclide for solid tumour treatment by using TCP and NTCP concepts'

*Computational and Mathematical Methods in Medicine*, VOL. 2015, 284360. DOI: 10.1155/2015/284360

**Monte Carlo calculation of radioimmunotherapy with ^{90}Y-, ^{177}Lu-, ^{131}I-, ^{124}I-, and ^{188}Re-Nanoobjects: Choice of the best radionuclide for solid tumour treatment by using TCP and NTCP concepts.** / Lucas, S.; Feron, O.; Gallez, B.; Masereel, B.; Michiels, C.; Vander Borght, T.

Résultats de recherche: Contribution à un journal/une revue › Article

TY - JOUR

T1 - Monte Carlo calculation of radioimmunotherapy with 90Y-, 177Lu-, 131I-, 124I-, and 188Re-Nanoobjects: Choice of the best radionuclide for solid tumour treatment by using TCP and NTCP concepts

AU - Lucas,S.

AU - Feron,O.

AU - Gallez,B.

AU - Masereel,B.

AU - Michiels,C.

AU - Vander Borght,T.

PY - 2015

Y1 - 2015

N2 - Radioimmunotherapy has shown that the use of monoclonal antibodies combined with a radioisotope like 131I or 90Y still remains ineffective for solid and radioresistant tumour treatment. Previous simulations have revealed that an increase in the number of 90Y labelled to each antibody or nanoobject could be a solution to improve treatment output. It now seems important to assess the treatment output and toxicity when radionuclides such as 90Y, 177Lu, 131I, 124I, and 188Re are used. Tumour control probability (TCP) and normal tissue complication probability (NTCP) curves versus the number of radionuclides per nanoobject were computed with MCNPX to evaluate treatment efficacy for solid tumours and to predict the incidence of surrounding side effects. Analyses were carried out for two solid tumour sizes of 0.5 and 1.0 cm radius and for nanoobject (i.e., a radiolabelled antibody) distributed uniformly or nonuniformly throughout a solid tumour (e.g., Non-small-cell-lung cancer (NSCLC)). 90Y and 188Re are the best candidates for solid tumour treatment when only one radionuclide is coupled to one carrier. Furthermore, regardless of the radionuclide properties, high values of TCP can be reached without toxicity if the number of radionuclides per nanoobject increases.

AB - Radioimmunotherapy has shown that the use of monoclonal antibodies combined with a radioisotope like 131I or 90Y still remains ineffective for solid and radioresistant tumour treatment. Previous simulations have revealed that an increase in the number of 90Y labelled to each antibody or nanoobject could be a solution to improve treatment output. It now seems important to assess the treatment output and toxicity when radionuclides such as 90Y, 177Lu, 131I, 124I, and 188Re are used. Tumour control probability (TCP) and normal tissue complication probability (NTCP) curves versus the number of radionuclides per nanoobject were computed with MCNPX to evaluate treatment efficacy for solid tumours and to predict the incidence of surrounding side effects. Analyses were carried out for two solid tumour sizes of 0.5 and 1.0 cm radius and for nanoobject (i.e., a radiolabelled antibody) distributed uniformly or nonuniformly throughout a solid tumour (e.g., Non-small-cell-lung cancer (NSCLC)). 90Y and 188Re are the best candidates for solid tumour treatment when only one radionuclide is coupled to one carrier. Furthermore, regardless of the radionuclide properties, high values of TCP can be reached without toxicity if the number of radionuclides per nanoobject increases.

UR - http://www.scopus.com/inward/record.url?scp=84934947426&partnerID=8YFLogxK

U2 - 10.1155/2015/284360

DO - 10.1155/2015/284360

M3 - Article

VL - 2015

JO - Computational and Mathematical Methods in Medicine

T2 - Computational and Mathematical Methods in Medicine

JF - Computational and Mathematical Methods in Medicine

SN - 1748-670X

M1 - 284360

ER -

^{90}Y-,

^{177}Lu-,

^{131}I-,

^{124}I-, and

^{188}Re-Nanoobjects: Choice of the best radionuclide for solid tumour treatment by using TCP and NTCP concepts. Computational and Mathematical Methods in Medicine. 2015;2015. 284360. Disponible �, DOI: 10.1155/2015/284360